Home >> Research Area >>Angiogenesis>>HIF>> FG-4592 (ASP1517)

FG-4592 (ASP1517)

HIF prolyl-hydroxylase inhibitor CAS# 808118-40-3

FG-4592 (ASP1517)

Catalog No. BCC2227----Order now to get a substantial discount!

Product Name & Size Price Stock
FG-4592 (ASP1517): 5mg $35 In Stock
FG-4592 (ASP1517): 10mg Please Inquire In Stock
FG-4592 (ASP1517): 20mg Please Inquire Please Inquire
FG-4592 (ASP1517): 50mg Please Inquire Please Inquire
FG-4592 (ASP1517): 100mg Please Inquire Please Inquire
FG-4592 (ASP1517): 200mg Please Inquire Please Inquire
FG-4592 (ASP1517): 500mg Please Inquire Please Inquire
FG-4592 (ASP1517): 1000mg Please Inquire Please Inquire
Related Products
  • BAY 87-2243

    Catalog No.:BCC4131
    CAS No.:1227158-85-1
  • PX 12

    Catalog No.:BCC2436
    CAS No.:141400-58-0
  • DMOG

    Catalog No.:BCC2433
    CAS No.:89464-63-1
  • KC7F2

    Catalog No.:BCC2434
    CAS No.:927822-86-4
  • IOX2(Glycine)

    Catalog No.:BCC2229
    CAS No.:931398-72-0

Quality Control of FG-4592 (ASP1517)

Number of papers citing our products

Chemical structure

FG-4592 (ASP1517)

3D structure

Chemical Properties of FG-4592 (ASP1517)

Cas No. 808118-40-3 SDF Download SDF
PubChem ID 11256664 Appearance Powder
Formula C19H16N2O5 M.Wt 352.34
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Roxadustat
Solubility DMSO : ≥ 100 mg/mL (283.82 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
SMILES CC1=NC(=C(C2=C1C=C(C=C2)OC3=CC=CC=C3)O)C(=O)NCC(=O)O
Standard InChIKey YOZBGTLTNGAVFU-UHFFFAOYSA-N
Standard InChI InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of FG-4592 (ASP1517)

DescriptionFG-4592 is an inhibitor of HIF α prolyl hydroxylase.
TargetsHIF α prolyl hydroxylase    

Protocol

Cell Assay [1]
The left eye of each rat is retro-orbitally injected with 25 mg/kg FG-4592 every 2 days, and an equal volume of 20% DMSO diluted with 0.9% NaCl is administrated with retro-orbital injection and served as the control. The retinae (attached, 1 day, 3 days, 5 days, and 7 days after RD) are homogenized and lysed with buffer containing 50 mM hydroxymethyl(Tris)-aminomethane(HCl), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and a protease inhibitor tablet. Samples are run on 8% to 12% 2-hydroxyethyl (Bis)-hydroxymethyl (Tris) gel electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membranes (0.2-mm pores). After blocking with 3% nonfat dried milk, the membranes are incubated overnight with primary antibody HIF-1α, LC3, BNIP3, autophagy-related gene 5 (Atg5), and β-actin. The blotted membranes are then incubated for 60 minutes at room temperature with a horseradish peroxidase (HRP)-labeled secondary antibody. Immunoreactive bands are visualized by enhanced chemiluminescence (ECL) and detected with an Amersham Imager 600. A minimum of three rats are used for each condition.

Animal Administration [1]
The rats are anesthetized with 1% sodium pentobarbital, and the pupils are dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride eye drops. In each rat, the sclera is punctured approximately 1.5 mm posterior to the limbus with a 30-gauge needle with special caution taken to avoid damaging the lens. The needle is slowly advanced into the vitreous cavity through the sclerotomy and then to the subretinal space by producing a small hole in the peripheral retina. Sodium hyaluronate (10 mg/mL) is slowly injected until almost two-thirds of the neurosensory retina detached from the underlying RPE. RD is confirmed for each rat by a surgical microscope. The blebs of RD are created and remained essentially stable for 7 days. All of the procedure steps are performed on the left eyes of the control group, except for the introduction of the subretinal injector and injection of the sodium hyaluronate. A total of 102 rats are used, and all animal experiments contained at least three rats per group. FG-4592 is dissolved in 20% dimethyl sulfoxide (DMSO) and diluted with 0.9% sodium chloride (NaCl). The left eye of each rat is retro-orbitally injected with 25 mg/kg FG-4592 every 2 days, and an equal volume of 20% DMSO diluted with 0.9% NaCl is administrated with retro-orbital injection and served as the control. All of the detection time points are selected at 4 to 6 hours after retro-orbital injection.

References:
[1]. Liu H, et al. Prolyl-4-Hydroxylases Inhibitor Stabilizes HIF-1α and Increases Mitophagy to Reduce Cell Death After Experimental Retinal Detachment. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):1807-15. [2]. Yu Y, et al. Hypoxia enhances tenocyte differentiation of adipose-derived mesenchymal stem cells by inducing hypoxia-inducible factor-1α in a co-culture system. Cell Prolif. 2016 Apr;49(2):173-84.

FG-4592 (ASP1517) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

FG-4592 (ASP1517) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of FG-4592 (ASP1517)

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8382 mL 14.1908 mL 28.3817 mL 56.7634 mL 70.9542 mL
5 mM 0.5676 mL 2.8382 mL 5.6763 mL 11.3527 mL 14.1908 mL
10 mM 0.2838 mL 1.4191 mL 2.8382 mL 5.6763 mL 7.0954 mL
50 mM 0.0568 mL 0.2838 mL 0.5676 mL 1.1353 mL 1.4191 mL
100 mM 0.0284 mL 0.1419 mL 0.2838 mL 0.5676 mL 0.7095 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on FG-4592 (ASP1517)

FG-4592 (also known as ASP1517), 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic acid, is a potent small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH), an enzyme up-regulating the expression of endogenous human erythropoietin (Epo). It is currently being investigated as an oral treatment for anemia associated with chronic kidney disease (CKD). Unlike other anemia treating agents, erythropoiesis-stimulating agents (ESAs), FG-4592 inhibits HIF, through a distinctive mechanism, by stabilization of HIF. According to previous studies, FG-4592 is capable of correcting and maintaining hemoglobin levels in CKD patients not receiving dialysis and in patients of end-stage renal disease who receives dialysis but do not need intravenous iron supplement.

Reference

1. Luis Borges. Different modalities of erythropoiesis stimulating agents. Port J Nephrol Hypert 2010; 24(2): 137-145
2. “FibroGen and Astellas announce initiation of phase 3 trial of FG-4592/ASP1517 for treatment of anemia of chronic kidney disease” Fibrogen Press Release. Dec 11 2012
3. “FibroGen announces initiation of phase 2b studies of FG-4592, an oral HIF prolyl hydroxylase inhibitor, for treatment of anemia”

Featured Products
New Products
 

Description

Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.

Keywords:

FG-4592 (ASP1517),808118-40-3,Roxadustat,Natural Products,HIF, buy FG-4592 (ASP1517) , FG-4592 (ASP1517) supplier , purchase FG-4592 (ASP1517) , FG-4592 (ASP1517) cost , FG-4592 (ASP1517) manufacturer , order FG-4592 (ASP1517) , high purity FG-4592 (ASP1517)

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: